JUA clinical guidelines for benign prostatic hyperplasia

International Journal of Urology

Volumn 18, Issue 11, 2011, Pages

  Homma, Yukio ^a   Gotoh, Momokazu ^b   Yokoyama, Osamu ^c   Masumori, Naoya ^d   Kawauchi, Akihiro ^e   Yamanishi, Tomonori ^f   Ishizuka, Osamu ^g   Seki, Narihito ^h   Kamoto, Toshiyuki ⁱ   Nagai, Atsushi ^j   Ozono, Seiichiro ^k  

^a UNIVERSITY OF TOKYO   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF MIYAZAKI   (Japan)

^j KAWASAKI MEDICAL SCHOOL   (Japan)

^k HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

BPH; Guidelines; Male LUTS

Indexed keywords

ADRENERGIC RECEPTOR; ALFUZOSIN; ALLYLESTRENOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CERNITIN; CHLORMADINONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CREATININE; DUTASTERIDE; EVIPROSTAT; FINASTERIDE; FLAVOXATE; GOSHAJINKIGAN; GROWTH FACTOR; HACHIMIJIOGAN; NAFTOPIDIL; PARAPROST; PLANT MEDICINAL PRODUCT; PRAZOSIN; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ARTICLE; BIPOLAR TRANSURETHRAL RESECTION; CHINESE MEDICINE; CHOLELITHIASIS; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; EJACULATION DISORDER; ENUCLEATION; ERECTILE DYSFUNCTION; HELP SEEKING BEHAVIOR; HEMATURIA; HIGH INTENSITY FOCUSED ULTRASOUND; HOLMIUM LASER ENUCLEATION; HUMAN; INCISION; INTERSTITIAL LASER COAGULATION; KIDNEY FAILURE; LASER COAGULATION; LIBIDO DISORDER; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; LOWER URINARY TRACT SYMPTOM; MALE; MEDICAL HISTORY; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; POSTVOID RESIDUAL URINE VOLUME; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; STENT; SUPPLEMENTATION; TANSRECTAL HIGH INTENSITY FOCUSED ULTRASOUND; THROMBOSIS; TRANSURETHRAL ELECTROVAPORIZATION; TRANSURETHRAL ENUCLEATION; TRANSURETHRAL ETHANOL ABLATION; TRANSURETHRAL INCISION; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; URETHRAL STENT; URINALYSIS; URINARY TRACT INFECTION; URINE RETENTION; UROFLOWMETRY;

EID: 80355133827     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02861.x     Document Type: Article

References (356)

1. The Research Group on the Standardization of Urological Treatment. EBM-Based Guidelines for the Treatment of Benign Prostatic Hyperplasia. Jiho, Tokyo, 2001. (In Japanese.)
2. The Research Group on the Standardization of Urological Treatment. EBM-Based Guidelines for Urinary Incontinence. Jiho, Tokyo, 2004. (In Japanese.)
3. Yamaguchi O, Nishizawa O, Takeda M etal. Clinical guidelines for overactive bladder. Int. J. Urol. 2009; 16: 126-42.
4. Homma Y, Araki I, Igawa Y etal. Clinical guideline for male lower urinary tract symptoms. Int. J. Urol. 2009; 16: 775-90.
5. Homma Y, Ueda T, Ito T, Takei M, Tomoe H. Japanese guideline for diagnosis and treatment of interstitial cystitis. Int. J. Urol. 2009; 16: 4-16.
6. Committee for Establishment of the Clinical Guidelines for Nocturia of the Neurogenic Bladder Society. Clinical guidelines for nocturia. Int. J. Urol. 2010; 17: 397-409.
7. A Guideline on the Management of Benign Prostatic Hyperplasia (BPH). [Cited 31 May 2010.] Available from URL.
8. EAU Guidelines on Benign Prostatic Hyperplasia. [Cited 31 May 2010.] Available from URL.
9. McConnell J, Abrams P, Denis L, Khoury S, Roehrborn C (eds). Male Lower Urinary Tract Dysfunction. Evaluation and Management. Editions 21, Paris, 2006.
10. Roehrborn CG. Focus on lower urinary tract symptoms: nomenclature, diagnosis, and treatment options. Highlights from the 5th International Consultation on Benign Prostatic Hyperplasia June 25-27, 2000, Paris, France. Rev. Urol. 2001; 3: 139-45.
11. Abrams P, Cardozo L, Fall M etal. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002; 21: 167-78.
12. Hald T. Urodynamics in benign prostatic hyperplasia: a survey. Prostate Suppl. 1989; 2: 69-77.
13. Turkes A, Griffiths K. Molecular control of prostate growth. In: Kirby R, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P (eds). Textbook of Benign Prostatic Hyperplasia, 2nd edn. Isis Medical Media, Oxford, 2005; 29-68.
14. Nandeesha H. Benign prostatic hyperplasia: dietary and metabolic risk factors. Int. Urol. Nephrol. 2008; 40: 649-56.
15. Rosen R, Altwein J, Boyle P etal. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. 2003; 44: 637-49.
16. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J. Urol. 1984; 132: 474-9.
17. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989; 15 (Suppl. 2): 33-50.
18. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5years in randomly selected community men 40 to 79years old. J. Urol. 1999; 161: 1174-9.
19. Bosch JLHR, Bangma CH, Groeneveld FPMJ, Bohnen AM. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur. Urol. 2008; 53: 819-27.
20. Bosch JLHR, Bohnen AM, Groeneveld FP, Bernsen R. Validity of three calliper-based transrectal ultrasound methods and digital rectal examination in the estimation of prostate volume and its changes with age: the Krimpen study. Prostate 2005; 62: 353-63.
21. Masumori N, Tsukamoto T, Kumamoto Y etal. Age-related differences in internal prostatic architecture on transrectal ultrasonography: results of a community based survey in Japan. J. Urol. 1997; 157: 1718-22.
22. Fukuta F, Masumori N, Muto M, Miyamoto S, Igarashi M, Tsukamoto T. Does the prostate internal architecture on transrectal ultrasound predict future prostate growth? A 15-year longitudinal community-based study of benign prostatic hyperplasia in Japan. Eur. Urol. Suppl. 2008; 7: 128 (Abstract 231).
23. Lieber MM, Rhodes T, Jacobson DJ etal. Natural history of benign prostatic enlargement: long-term longitudinal population-based study of prostate volume doubling times. BJU Int. 2010; 105: 214-19.
24. Tsukamoto T, Masumori N. Epidemiology and natural history of benign prostatic hyperplasia. Int. J. Urol. 1997; 4: 233-46.
25. Tsukamoto T, Kumamoto Y, Masumori N etal. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J. Urol. 1995; 154: 391-5.
26. Homma Y, Kawabe K, Tsukamoto T etal. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the International Prostate Symptom Score. Int. J. Urol. 1997; 4: 40-6.
27. Homma Y, Yamaguchi O, Hayashi K, Neurogenic Bladder Society Committee. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 2006; 68: 560-4.
28. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J. Urol. 1996; 155: 595-600.
29. Lee AJ, Garraway WM, Simpson RJ, Fisher W, King D. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur. Urol. 1998; 34: 325-32.
30. Masumori N, Tsukamoto T, Rhodes T, Girman CJ. Natural history of lower urinary tract symptoms in men: results of a longitudinal community-based study in Japan. Urology 2003; 61: 956-60.
31. Masumori N, Tsukamoto T, Kumamoto Y etal. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J. Urol. 1996; 155: 1324-7.
32. Roberts RO, Jacobsen SJ, Jacobson DJ, Rhodes T, Girman CJ, Lieber MM. Longitudinal changes in peak urinary flow rates in a community-based cohort. J. Urol. 2000; 163: 107-13.
33. St Sauver JL, Jacobson DJ, Girman CJ, Lieber MM, McGree ME, Jacobsen SJ. Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. J. Urol. 2006; 175: 1018-22.
34. Bosch JLHR, Hop WCJ, Kirkels WJ, Schröder FH. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 1995; 46 (Suppl. 3A): 34-40.
35. Jacobsen SJ, Guess HA, Panser L etal. A population based study of health care-seeking behavior for treatment of urinary symptoms: the Olmsted County study of urinary symptoms and health status among men. Arch. Fam. Med. 1993; 2: 729-35.
36. Masumori N, Tanaka Y, Takahashi A etal. Lower urinary tract symptoms of men seeking medical care: comparison of the symptoms found in the clinical setting and in a community study. Urology 2003; 62: 266-72.
37. Jacobsen SJ, Jacobson DJ, Girman CJ etal. Natural history of prostatism: risk factors for acute urinary retention. J. Urol. 1997; 158: 481-7.
38. Jacobsen SJ, Jacobson DJ, Girman CJ etal. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J. Urol. 1999; 162: 1301-6.
39. Marberger MJ.Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. Prowess Study Group. Urology 1998; 51: 677-86.
40. McConnell JD, Bruskewitz R, Walsh P etal. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N. Engl. J. Med. 1998; 338: 557-63.
41. Roehrborn CG, McConnell J, Jacobs S etal. Baseline prostate volume and serum PSA predict rate of prostate growth: analysis of the MTOPS data. J. Urol. 2003; 169 (Suppl.): 364 (Abstract 1361).
42. Barry MJ, Fowler FJ, Bin L, Pitts JC III, Harris CJ, Mulley AG Jr. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J. Urol. 1997; 157: 10-15.
43. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N. Engl. J. Med. 1995; 332: 75-9.
44. Roehrborn CG, McConnell JD, Lieber M etal. Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-80.
45. Crawford ED, Wilson SS, McConnell JD etal. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J. Urol. 2006; 175: 1422-7.
46. McConnell JD, Roehrborn CG, Bautista OM etal. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003; 349: 2387-98.
47. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest. Urol. 1987; 15: 340-5.
48. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol. Clin. North Am. 1990; 17: 477-86.
49. Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular, and molecular control of prostatic development. Dev. Biol. 2003; 253: 165-74.
50. Mishra VC, Allen DJ, Nicolaou C etal. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int. 2007; 100: 327-31.
51. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur. Urol. 2008; 54: 1379-84.
52. Giri D, Ittmann M. Interleukin-1α is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am. J. Pathol. 2000; 157: 249-55.
53. Matityahou A, Rosenzweig N, Golomb E. Rapid proliferation of prostatic epithelial cells in spontaneously hypertensive rats: a model of spontaneous hypertension and prostate hyperplasia. J. Androl. 2003; 24: 263-9.
54. 1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002; 5: 88-95.
55. 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br. J. Pharmacol. 1996; 119: 797-803.
56. Kojima Y, Sasaki S, Shinoura H, Hayashi Y, Tsujimoto G, Kohri K. Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate 2006; 66: 761-7.
57. 1A-adrenoceptor gene knockout. Br. J. Pharmacol. 2008; 155: 1224-34.
58. 1d-adrenoceptor. J. Urol. 2005; 174: 370-4.
59. Yokoyama O, Yusup A, Oyama N, Aoki Y, Miwa Y, Akino H. Improvement of bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats. J. Urol. 2007; 177: 771-5.
60. 1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity. World J. Urol. 2010; 28: 609-14.
61. Rosier PFWM, de la Rosette JJMCH. Is there a correlation between prostate size and bladder-outlet obstruction? World J. Urol. 1995; 13: 9-13.
62. el Din KE, Kiemeney LALM, de Wildt MJAM, Rosier PFWH, Debruyne FMJ, de la Rosette JJMCH. The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score. J. Urol. 1996; 156: 1020-5.
63. Chia SJ, Heng CT, Chan SP, Foo KT. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int. 2003; 91: 371-4.
64. van Venrooij GEPM, Boon TA. The value of symptom score, quality of life score, maximal urinary flow rate, residual volume and prostate size for the diagnosis of obstructive benign prostatic hyperplasia: a urodynamic analysis. J. Urol. 1996; 155: 2014-18.
65. Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur. Urol. 2008; 54: 419-26.
66. Romanzi LJ, Groutz A, Heritz DM, Blaivas JG. Involuntary detrusor contractions: correlation of urodynamic data to clinical categories. Neurourol. Urodyn. 2001; 20: 249-57.
67. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J. Urol. 2001; 166: 550-3.
68. Mori K, Noguchi M, Matsuo M, Nomata K, Suematsu T, Kanetake H. Decreased cellular membrane expression of gap junctional protein, connexin 43, in rat detrusor muscle with chronic partial bladder outlet obstruction. Urology 2005; 65: 1254-8.
69. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RCL. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J. Urol. 1979; 121: 640-2.
70. Abarbanel J, Marcus E-L. Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. Urology 2007; 69: 436-40.
71. Madersbacher S, Klingler HC, Schatzl G, Stulnig T, Schmidbauer CP, Marberger M. Age related urodynamic changes in patients with benign prostatic hyperplasia. J. Urol. 1996; 156: 1662-7.
72. Elbadawi A, Diokno AC, Millard RJ. The aging bladder: morphology and urodynamics. World J. Urol. 1998; 16 (Suppl. 1): S10-34.
73. Azadzoi KM, Radisavljevic ZM, Golabek T, Yalla SV, Siroky MB. Oxidative modification of mitochondrial integrity and nerve fiber density in the ischemic overactive bladder. J. Urol. 2010; 183: 362-9.
74. Mitterberger M, Pallwein L, Gradl J etal. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int. 2007; 99: 831-5.
75. Speakman MJ, Brading AF, Gilpin CJ, Dixon JS, Gilpin SA, Gosling JA. Bladder outflow obstruction: a cause of denervation supersensitivity. J. Urol. 1987; 138: 1461-6.
76. Azadzoi KM, Radisavljevic ZM, Siroky MB. Effects of ischemia on tachykinin-containing nerves and neurokinin receptors in the rabbit bladder. Urology 2008; 71: 979-83.
77. Christ GJ, Day NS, Day M etal. Increased connexin43-mediated intercellular communication in a rat model of bladder overactivity in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003; 284: R1241-8.
78. de Jongh R, van Koeveringe GA, van Kerrebroeck PEV, Markerink-van Ittersum M, de Vente J, Gillespie JI. Alterations to network of NO/cGMP-responsive interstitial cells induced by outlet obstruction in guinea-pig bladder. Cell Tissue Res. 2007; 330: 147-60.
79. Sibley GNA. The physiological response of the detrusor muscle to experimental bladder outflow obstruction in the pig. Br. J. Urol. 1987; 60: 332-6.
80. Takahashi N, Shiomi H, Kushida N etal. Obstruction alters muscarinic receptor-coupled RhoA/Rho-kinase pathway in the urinary bladder of the rat. Neurourol. Urodyn. 2009; 28: 257-62.
81. Birder LA, de Groat WC. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat. Clin. Prac. Urol. 2007; 4: 46-54.
82. Birder LA, Nakamura Y, Kiss S etal. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat. Neurosci. 2002; 5: 856-60.
83. Araki I, Du S, Kamiyama M etal. Overexpression of epithelial sodium channels in epithelium of human urinary bladder with outlet obstruction. Urology 2004; 64: 1255-60.
84. Sadananda P, Shang F, Liu L, Mansfield KJ, Burcher E. Release of ATP from rat urinary bladder mucosa: role of acid, vanilloids and stretch. Br. J. Pharmacol. 2009; 158: 1655-62.
85. Kim JC, Yoo JS, Park EY, Hong SH, Seo SI, Hwang T-K. Muscarinic and purinergic receptor expression in the urothelium of rats with detrusor overactivity induced by bladder outlet obstruction. BJU Int. 2008; 101: 371-5.
86. Masuda H, Kihara K, Saito K etal. Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int. 2008; 101: 775-80.
87. Yokoyama O, Nagano K, Kawaguchi K, Ueki O, Ohkawa M. The influence of prostatic urethral anesthesia in overactive detrusor in patients with benign prostatic hyperplasia. J. Urol. 1994; 151: 1554-6.
88. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3, 885 patients. J. Urol. 1989; 141: 243-7.
89. Foley SJ, Bailey DM. Microvessel density in prostatic hyperplasia. BJU Int. 2000; 85: 70-3.
90. Pareek G, Shevchuk M, Armenakas NA etal. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J. Urol. 2003; 169: 20-3.
91. O'Connor RC, Laven BA, Bales GT, Gerber GS. Nonsurgical management of benign prostatic hyperplasia in men with bladder calculi. Urology 2002; 60: 288-91.
92. Gerber GS, Goldfischer ER, Karrison TG, Bales GT. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 1997; 49: 697-702.
93. Barry MJ, Fowler FJ Jr, O'Leary MP etal. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol. 1992; 148: 1549-57.
94. Homma Y, Tsukamoto T, Yasuda K, Ozono S, Yoshida M, Shinji M. Linguistic validation of Japanese version of International Prostate Symptom Score and BPH impact index. Nippon Hinyokika Gakkai Zasshi 2002; 93: 669-80. (In Japanese with an English abstract.)
95. Homma Y, Tsukamoto T, Yasuda K, Ozono S, Yoshida M, Yamaguchi T. Evaluation of psychometric properties of Japanese version of international prostate symptom score and BPH impact index. Nippon Hinyokika Gakkai Zasshi 2003; 94: 560-9. (In Japanese with an English abstract.)
96. Coyne K, Revicki D, Hunt T etal. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual. Life Res. 2002; 11: 563-74.
97. Homma Y, Yoshida M, Seki N etal. Symptom assessment tool for overactive bladder syndrome: overactive bladder symptom score. Urology 2006; 68: 318-23.
98. Homma Y, Yoshida M, Yamanishi T, Gotoh M. Core lower urinary tract symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int. J. Urol. 2008; 15: 816-20.
99. Gupta A, Aragaki C, Gotoh M etal. Relationship between prostate specific antigen and indexes of prostate volume in Japanese men. J. Urol. 2005; 173: 503-6.
100. Tsukamoto T, Endo Y, Narita M. Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. Int. J. Urol. 2009; 16: 745-50.
101. Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology 1998; 51 (Suppl. 4A): 19-22.
102. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405.
103. Homma Y, Araki I, Igawa Y etal. Clinical Guideline for Male Lower Urinary Tract Symptoms. Blackwell, Tokyo, 2008.
104. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 1999; 36: 1-13.
105. 1-adrenoceptors. Jpn. J. Pharmacol. 1999; 79: 447-54.
106. 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J. Urol. 1990; 144: 908-12.
107. Wilt TJ, MacDonald R, Nelson D. Tamsulosin for lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J. Urol. 2002; 167: 177-83.
108. Yamaguchi O, Fukaya Y, Shiraiwa Y etal. Clinical evaluation of naftopidil (KT-611) in micturition disorder associated with benign prostatic hyperplasia: a doubleblind comparative study using prazosin hydrochloride as a comparator. Journal of Clinical Therapeutics and Medicine 1992; 8: 699-722. (In Japanese with an English abstract.)
109. Yamanishi T, Yasuda K, Kamai K etal. Single-blind, randomized controlled study of the clinical and urodynamic effects of an α-blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia. Int. J. Urol. 2004; 11: 501-9.
110. 1-adrenoceptors and native tissues. Mol. Pharmacol. 1995; 48: 250-8.
111. 1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006; 98: 1019-24.
112. 1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J. Urol. 2009; 181: 2634-40.
113. Tsukamoto T, Endo Y, Narita M. Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled, parallel-group, dose response study. Acta Urol. Jpn. 2009; 55: 209-14. (In Japanese with an English abstract.)
114. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J. Clin. Endocrinol. Metab. 2004; 89: 2179-84.
115. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G., ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2(dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41.
116. Gormley GJ, Stoner E, Bruskewitz RC etal. The effect of finasteride in men with benign prostatic hyperplasia. Finasteride Study Group. N. Engl. J. Med. 1992; 327: 1185-91.
117. Yoshida H, Haraguchi C, Ogawa Y etal. Clinical effects of chlormadinone acetate (PROSTAL®) on patients with prostatic hypertrophy-with reference to estimation of size and weight of prostate by means of transrectal ultrasonotomography. Acta Urol. Jpn. 1983; 29: 1419-26. (In Japanese with an English abstract.)
118. Aso Y, Homma Y, Kumamoto Y etal. Phase III study of 5α-reductase inhibitor, MK-906 in patients with benign prostatic hyperplasia: a comparative double blind study with chlormadinone acetate long acting tablets. Jpn. J. Urol. Surg. 1995; 8: 237-56 (In Japanese.)
119. Aso Y, Homma Y, Kumamoto Y etal. Phase III study of 5α-reductase inhibitor, MK-906 in patients with benign prostatic hyperplasia (PART 2) - study of equivalence of clinical efficacy with chlormadinone acetate long acting tablets. Jpn. J. Urol. Surg. 1996; 9: 335-42. (In Japanese.)
120. Shida K, Koyanagi T, Kawakura K etal. Clinical effects of allylestrenol on benign prostatic hypertrophy by double-blind method. Acta Urol. Jpn. 1986; 32: 625-48. (In Japanese with an English abstract.)
121. Kumamoto Y, Yamaguchi Y, Sato Y etal. Effects of anti-androgens on sexual function double-blind comparative studies on allylestrenol and chlormadinone acetate part I: nocturnal penile tumescence monitoring. Acta Urol. Jpn. 1990; 36: 213-26. (In Japanese with an English abstract.)
122. Kumamoto Y, Yamaguchi Y, Sato Y etal. Effects of anti-androgens on sexual function double-blind comparative studies on allylestrenol and chlormadinone acetate part II: self-assessment questionnaire method. Acta Urol. Jpn. 1990; 36: 227-44. (In Japanese with an English abstract.)
123. Nakano H, Hiromoto N, Nihira H etal. Clinical effect of Eviprostat in patients with benign prostatic hyperplasia - a double-blind study. Acta Urol. Jpn. 1975; 21: 433-52. (In Japanese with an English abstract.)
124. Sasaki S, Maekawa M, Kishimoto T etal. Effectiveness of Eviprostat for benign prostatic hyperplasia - evaluation by means of double blind method. Nishinihon J. Urol. 1975; 37: 647-60. (In Japanese with an English abstract.)
125. Ishigooka M, Hashimoto T, Hayami S, Tomaru M, Nakada T, Mitobe K. Clinical and retrospective evaluation of Eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia. Int. Urol. Nephrol. 1995; 27: 61-6.
126. Tomita M, Egawa S, Ikemoto I etal. One-week effects of tamsulosin on benign prostatic hyperplasia assessed with a daily symptom score. Acta Urol. Jpn. 2009; 55: 193-7. (In Japanese with an English abstract.)
127. Miwa K, Moriyama Y, Masue T etal. The efficacy of Eviprostat® for pelvic discomfort in benign prostatic hyperplasia patients. Jpn. J. Urol. Surg. 2008; 21: 807-14. (In Japanese with an English abstract.)
128. 1-adrenoceptor blocker. Acta Urol. Jpn. 2008; 54: 341-4. (In Japanese with an English abstract.)
129. Buck AC, Cox R, Rees RWH, Ebeling L, John A. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study. Br. J. Urol. 1990; 66: 398-404.
130. Wilt T, MacDonald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia (Review). Cochrane Database Syst. Rev. 2000; (2): CD001042.
131. MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000; 85: 836-41.
132. Elist J. Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study. Urology 2006; 67: 60-3.
133. Yamaguchi O, Shiraiwa Y, Kobayashi M etal. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multiinstitutional, Paraprost-controlled study. Urol. Int. 1990; 45 (Suppl. 1): 40-6.
134. Ishizuka O, Yamanishi T, Gotoh M etal. LUTS: new evidence-clinical efficacy of Kampo formulations focusing on goshajinkigan. Urology View 2009; 7: 81-4. (In Japanese.)
135. Fujiuchi Y, Watanabe A, Fuse H. Effect of goshajinkigan on storage symptoms in prostatic disease: fundamental researches of Chinese herbal medicine for voiding dysfunction and its future aspects. Acta Urol. Jpn. 2008; 54: 463-6. (In Japanese with an English abstract.)
136. Dahm TL, Ostri P, Kristensen JK etal. Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation. Urol. Int. 1995; 55: 205-8.
137. 1-adrenoceptor blocker. Acta Urol. Jpn. 2008; 54: 173-7. (In Japanese with an English abstract.)
138. Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006; 97: 1003-6.
139. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. A randomized controlled trial. JAMA 2006; 296: 2319-28.
140. Abrams P, Kaplan SA, DeKoning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J. Urol. 2006; 175: 999-1004.
141. Barendrecht MM, Oelke M, Laguna MP, Michel MC. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int. 2007; 99: 749-52.
142. Wein AJ, Hanno PM, Dixon DO, Raezer DM, Benson GS. The effect of oral bethanechol chloride on the cystometrogram of the normal male adult. J. Urol. 1978; 120: 330-1.
143. Shah PJR, Abrams PH, Choa RG etal. Distigmine bromide and post-prostatectomy voiding. Br. J. Urol. 1983; 55: 229-32.
144. Tanaka Y, Masumori N, Itoh N, Furuya S, Nishizawa O, Tsukamoto T. Symptomatic and urodynamic improvement by oral distigmine bromide in poor voiders after transurethral resection of the prostate. Urology 2001; 57: 270-4.
145. Yamanishi T, Yasuda K, Kamai T etal. Combination of a cholinergic drug and an α-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int. J. Urol. 2004; 11: 88-96.
146. Burnett AL. Nitric oxide control of lower genitourinary tract functions: a review. Urology 1995; 45: 1071-83.
147. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J. Urol. 2007; 177: 1071-7.
148. Guven EO, Balbay MD, Mete K, Serefoglu EC. Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int. Urol. Nephrol. 2009; 41: 287-92.
149. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur. Urol. 2007; 51: 1717-23.
150. Roehrborn CG, McVary KT, Elion-Mboussa A, Virktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J. Urol. 2008; 180: 1228-34.
151. Porst H, McVary KT, Montorsi F etal. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur. Urol. 2009; 56: 727-36.
152. McVary KT, Roehrborn CG, Kaminetsky JC etal. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 2007; 177: 1401-7.
153. Bechara A, Romano S, Casabé A etal. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J. Sex. Med. 2008; 5: 2170-8.
154. Gass R. Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake. BJU Int. 2002; 90: 649-54.
155. Platz EA, Kawachi I, Rimm EB etal. Physical activity and benign prostatic hyperplasia. Arch. Intern. Med. 1998; 158: 2349-56.
156. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J. Clin. Epidemiol. 2001; 54: 935-44.
157. Orsini N, RashidKhani B, Andersson S-O, Karlberg L, Johansson J-E, Wolk A. Long-term physical activity and lower urinary tract symptoms in men. J. Urol. 2006; 176: 2546-50.
158. Netto NR Jr, de Lima ML, Netto MR, D'Ancona CAL. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology 1999; 53: 314-16.
159. Ikuerowo SO, Ogunade AA, Ogunlowo TO, Uzodimma CC, Esho JO. The burden of prolonged indwelling catheter after acute urinary retention in Ikeja - Lagos, Nigeria. BMC Urol. 2007; 7: 16.
160. Turi MH, Hanif S, Fasih Q, Shaikh MA. Proportion of complications in patients practicing clean intermittent self-catheterization (CISC) vs indwelling catheter. J. Pak. Med. Assoc. 2006; 56: 401-4.
161. Ghalayini IF, Al-Ghazo MA, Pickard RS. A prospective randomized trial comparing transurethral prostatic resection and clean intermittent self-catheterization in men with chronic urinary retention. BJU Int. 2005; 96: 93-7.
162. Thiel DD, Petrou SP. Electroresection and open surgery. Urol. Clin. North Am. 2009; 36: 461-70.
163. Serretta V, Morgia G, Fondacaro L etal. Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions. Urology 2002; 60: 623-7.
164. Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): the endourologic alternative to open prostatectomy. Eur. Urol. 2006; 49: 87-91.
165. Noguera RS, Rodríguez RC. Open adenomectomy: past, present and future. Curr. Opin. Urol. 2008; 18: 34-40.
166. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU Int. 1999; 83: 227-37.
167. Miano R, de Nunzio C, Asimakopoulos AD, Germani S, Tubaro A. Treatment options for benign prostatic hyperplasia in older men. Med. Sci. Monit. 2008; 14: RA94-102.
168. Madersbacher S, Lackner J, Brössner C etal. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23 123 cases. Eur. Urol. 2005; 47: 499-504.
169. Orandi A. Transurethral incision of the prostate. J. Urol. 1973; 110: 229-31.
170. Dørflinger T, Jensen FS, Krarup T, Walter S. Transurethral prostatectomy compared with incision of the prostate in the treatment of prostatism caused by small benign prostate glands. Scand. J. Urol. Nephrol. 1992; 26: 333-8.
171. Riehmann M, Knes JM, Heisey D, Madsen PO, Bruskewitz RC. Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 1995; 45: 768-75.
172. Yang Q, Peters TJ, Donovan JL, Wilt TJ, Abrams P. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomised controlled trials. J. Urol. 2001; 165: 1526-32.
173. Tkocz M, Prajsner A. Comparison of long-term results of transurethral incision of the prostate with transurethral resection of the prostate, in patients with benign prostatic hypertrophy. Neurourol. Urodyn. 2002; 21: 112-16.
174. ®). J. Endourol. 2004; 18: 959-64.
175. Rassweiler J, Schulze M, Stock C, Teber D, de la Rosette J. Bipolar transurethral resection of the prostate: technical modifications and early clinical experience. Minim. Invasive Ther. Allied Technol. 2007; 16: 11-21.
176. Michielsen DP, Debacker T, De Boe V etal. Bipolar transurethral resection in saline: an alternative surgical treatment for bladder outlet obstruction? J. Urol. 2007; 178: 2035-9.
177. Ho HSS, Cheng CWS. Bipolar transurethral resection of prostate: a new reference standard? Curr. Opin. Urol. 2008; 18: 50-5.
178. Mamoulakis C, Trompetter M, de la Rosette J. Bipolar transurethral resection of the prostate: the "golden standard" reclaims its leading position. Curr. Opin. Urol. 2009; 19: 26-32.
179. Dincel C, Samli MM, Guler C, Demirbas M, Karalar M. Plasma kinetic vaporization of the prostate: clinical evaluation of a new technique. J. Endourol. 2004; 18: 293-8.
180. Ho HS, Yip SKH, Lim KB, Fook S, Foo KT, Cheng CWS. A prospective randomized study comparing monopolar and bipolar transurethral resection of prostate using transurethral resection in saline (TURIS) system. Eur. Urol. 2007; 52: 517-24.
181. Erturhan S, Erbagci A, Seckiner I, Yagci F, Ustun A. Plasmakinetic resection of the prostate versus standard transurethral resection of the prostate: a prospective randomized trial with 1-year follow-up. Prostate Cancer Prostatic Dis. 2007; 10: 97-100.
182. de Sio M, Autorino R, Quarto G etal. Gyrus bipolar versus standard monopolar transurethral resection of the prostate: a randomized prospective trial. Urology 2006; 67: 69-72.
183. Iori F, Franco G, Leonardo C etal. Bipolar transurethral resection of prostate: clinical and urodynamic evaluation. Urology 2008; 71: 252-5.
184. Seckiner I, Yesilli C, Akduman B, Altan K, Mungan NA. A prospective randomized study for comparing bipolar plasmakinetic resection of the prostate with standard TURP. Urol. Int. 2006; 76: 139-43.
185. Singh H, Desai MR, Shrivastav P, Vani K. Bipolar versus monopolar transurethral resection of prostate: randomized controlled study. J. Endourol. 2005; 19: 333-8.
186. Tefekli A, Muslumanoglu AY, Baykal M, Binbay M, Tas A, Altunrende F. A hybrid technique using bipolar energy in transurethral prostate surgery: a prospective, randomized comparison. J. Urol. 2005; 174: 1339-43.
187. Yang S, Lin WC, Chang HK etal. Gyrus plasmasect: is it better than monopolar transurethral resection of prostate? Urol. Int. 2004; 73: 258-61.
188. Nuhoǧlu B, Ayyildiz A, Karagüzel E, Cebeci O, Germiyanoǧlu C. Plasmakinetic prostate resection in the treatment of benign prostate hyperplasia: results of 1-year follow up. Int. J. Urol. 2006; 13: 21-4.
189. Patankar S, Jamkar A, Dobhada S, Gorde V. PlasmaKinetic Superpulse transurethral resection versus conventional transurethral resection of prostate. J. Endourol. 2006; 20: 215-19.
190. Autorino R, de Sio M, D'Armiento M. Bipolar plasmakinetic technology for the treatment of symptomatic benign prostatic hyperplasia: evidence beyond marketing hype? BJU Int. 2007; 100: 983-5.
191. Mamoulakis C, Ubbink DT, de la Rosette JJMCH. Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur. Urol. 2009; 56: 798-809.
192. Gilling PJ, Kennett K, Das AK, Thompson D, Fraundorfer MR. Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. J. Endourol. 1989; 12: 457-9.
193. Seki N, Mochida O, Kinukawa N, Sagiyama K, Naito S. Holmium laser enucleation for prostatic adenoma: analysis of learning curve over the course of 70 consecutive cases. J. Urol. 2003; 170: 1847-50.
194. Seki N, Tatsugami K, Naito S. Holmium laser enucleation of the prostate: comparison of outcomes according to prostate size in 97 Japanese patients. J. Endourol. 2007; 21: 192-6.
195. Elzayat EA, Habib EI, Elhilali MM. Holmium laser enucleation of prostate for patients in urinary retention. Urology 2005; 66: 789-93.
196. Elzayat EA, Habib EI, Elhilali MM. Holmium laser enucleation of the prostate: a size-independent new "gold standard". Urology 2005; 66: 108-13.
197. Elzayat E, Habib EI, Elhilali MM. Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J. Urol. 2006; 175: 1428-32.
198. Matlaga BR, Kim SC, Kuo RL, Watkins SL, Lingeman JE. Holmium laser enucleation of the prostate for prostates of >125mL. BJU Int. 2006; 97: 81-4.
199. Shah HN, Mahajan AP, Hegde SS, Bansal MB. Peri-operative complications of holmium laser enucleation of the prostate: experience in the first 280 patients, and a review of literature. BJU Int. 2007; 100: 94-101.
200. Matlaga BR, Miller NL, Lingerman JE. Holmium laser treatment of benign prostatic hyperplasia: an update. Curr. Opin. Urol. 2007; 17: 27-31.
201. Gilling P. Holmium laser enucleation of the prostate (HoLEP). BJU Int. 2008; 101: 131-42.
202. Ahyai SA, Lehrich K, Kuntz RM. Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial. Eur. Urol. 2007; 52: 1456-64.
203. Tan AH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J. Urol. 2003; 170: 1270-4.
204. Kuntz RM, Ahyai S, Lehrich K, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. J. Urol. 2004; 172: 1012-16.
205. Wilson LC, Gilling PJ, Williams A etal. A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2years. Eur. Urol. 2006; 50: 569-73.
206. Briganti A, Naspro R, Gallina A etal. Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial. J. Urol. 2006; 175: 1817-21.
207. Gupta N, Sivaramakrishna, Kumar R, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40g. BJU Int. 2006; 97: 85-9.
208. Montorsi F, Naspro R, Salonia A etal. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J. Urol. 2004; 172: 1926-9.
209. Rigatti L, Naspro R, Salonia A etal. Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1year of follow-up? Urology 2006; 67: 1193-8.
210. Kuntz RM, Lehrich K. Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm: a randomized prospective trial of 120 patients. J. Urol. 2002; 168: 1465-9.
211. Naspro R, Suardi N, Salonia A etal. Holmium laser enucleation of the prostate versus open prostatectomy for prostates > 70g: 24-month follow-up. Eur. Urol. 2006; 50: 563-8.
212. Salonia A, Suardi N, Naspro R etal. Holmium laser enucleation versus open prostatectomy for benign prostatic hyperplasia: an inpatient cost analysis. Urology 2006; 68: 302-6.
213. Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur. Urol. 2008; 53: 160-8.
214. Shah HN, Mahajan AP, Sodha HS, Hegde S, Mohile PD, Bansal MB. Prospective evaluation of the learning curve for holmium laser enucleation of the prostate. J. Urol. 2007; 177: 1468-74.
215. Malek RS, Kuntzman RS, Barrett DM. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J. Urol. 2005; 174: 1344-8.
216. Rajbabu K, Chandrasekara SK, Barber NJ, Walsh K, Muir GH. Photoselective vaporization of the prostate with the potassium-titanyl-phosphate laser in men with prostates of >100mL. BJU Int. 2007; 100: 593-8.
217. Bachmann A, Ruszat R. The KTP-(greenlight-) laser - principles and experiences. Minim. Invasive Ther. Allied Technol. 2007; 16: 5-10.
218. Chandrasekera S, Muir G. Potassium titanyl phosphate laser prostatectomy: a review. Curr. Opin. Urol. 2007; 17: 22-6.
219. Pfitzenmaier J, Gilfrich C, Pritsch M etal. Vaporization of prostates of ≥ 80mL using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates of <80mL. BJU Int. 2008; 102: 322-7.
220. Hori Y, Kuromatsu I, Sugimura Y. Photoselective vaporization of the prostate using high power (80W) KTP laser: one year follow up of the first 101 patients in Japan. Int. J. Urol. 2008; 15: 1067-71.
221. Wosnitzer MS, Rutman MP. KTP/LBO laser vaporization of the prostate. Urol. Clin. North Am. 2009; 36: 471-83.
222. Nomura H, Seki N, Yamaguchi A, Naito S. Photoselective vaporization of the prostate: outcome according to the prostate size in a series of 102 Japanese patients. Int. J. Urol. 2009; 16: 87-90.
223. Bouchier-Hayes DM. Photoselective vaporization of the prostate: towards a new standard. Prostate Cancer Prostatic Dis. 2007; 10: S10-14.
224. Bachmann A, Schürch L, Ruszat R etal. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur. Urol. 2005; 48: 965-72.
225. Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70mL: a short-term prospective randomized trial. Urology 2008; 71: 247-51.
226. Tasci AI, Tugcu V, Sahin S, Zorluoglu F. Rapid communication: photoselective vaporization of the prostate versus transurethral resection of the prostate for the large prostate: a prospective nonrandomized bicenter trial with 2-year follow-up. J. Endourol. 2008; 22: 347-53.
227. Skolarikos A, Papachristou C, Athanasiadis G, Chalikopoulos D, Deliveliotis C, Alivizatos G. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80cc. J. Endourol. 2008; 22: 2333-40.
228. Neill MG, Gilling PJ, Kennett KM etal. Randomized trial comparing holmium laser enucleation of prostate with plasmakinetic enucleation of prostate for treatment of benign prostatic hyperplasia. Urology 2006; 68: 1020-4.
229. Hiraoka Y, Akimoto M. Transurethral enucleation of benign prostatic hyperplasia. J. Urol. 1989; 142: 1247-50.
230. Hiraoka Y, Shimizu Y, Iwamoto K, Takahashi H, Abe H. Trial of complete detachment of the whole prostate lobes in benign prostate hyperplasia by transurethral enucleation of the prostate. Urol. Int. 2007; 79: 50-4.
231. Zhao Z, Zeng G, Zhong W, Mai Z, Zeng S, Tao X. A prospective, randomised trial comparing plasmakinetic enucleation to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: three-year follow-up results. Eur. Urol. 2010; 58: 752-8.
232. Kursh ED, Concepcion R, Chan S, Hudson P, Ratner M, Eyre R. Interstitial laser coagulation versus transurethral prostate resection for treating benign prostatic obstruction: a randomized trial with 2-year follow-up. Urology 2003; 61: 573-8.
233. Muschter R, Sroka R, Perlmutter AP etal. High power interstitial laser coagulation of benign prostatic hyperplasia. J. Endourol. 1996; 10 (Suppl. 1): S197 (Abstract).
234. Terada N, Arai Y, Okubo K etal. Interstitial laser coagulation for management of benign prostatic hyperplasia: long-term follow-up. Int. J. Urol. 2004; 11: 978-82.
235. Daehlin L, Frugard J. Interstitial laser coagulation in the management of lower urinary tract symptoms suggestive of bladder outlet obstruction from benign prostatic hyperplasia: long-term follow-up. BJU Int. 2007; 100: 89-93.
236. Muschter R, Hofstetter A. Laser thermocoagulation of adenoma of the prostate using an interstitial approach. Ann. Urol. 1997; 31: 27-37.
237. Mulligan ED, Lynch TH, Mulvin D, Greene D, Smith JM, Fitzpatrick JM. High-intensity focused ultrasound in the treatment of benign prostatic hyperplasia. Br. J. Urol. 1997; 79: 177-80.
238. Nakamura K, Baba S, Saito S, Tachibana M, Murai M. High-intensity focused ultrasound energy for benign prostatic hyperplasia: clinical response at 6months to treatment using Sonablate 200. J. Endourol. 1997; 11: 197-201.
239. Sullivan LD, McLoughlin MG, Goldenberg LG, Gleave ME, Marich KW. Early experience with high-intensity focused ultrasound for the treatment of benign prostatic hypertrophy. Br. J. Urol. 1997; 79: 172-6.
240. Ohigashi T, Nakamura K, Nakashima J, Baba S, Murai M. Long-term results of three different minimally invasive therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: comparison at a single institute. Int. J. Urol. 2007; 14: 326-30.
241. Hirao Y, Ozono S, Fujimoto K, Hirayama A. HIFU (high intensity focused ultrasound) TUNA (transurethral needle ablation). Jpn. J. Endourol. and ESWL 2003; 16: 63-71. (In Japanese.)
242. Madersbacher S, Schatzl G, Djavan B, Stulnig T, Marberger M. Long-term outcome of transrectal high-intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur. Urol. 2000; 37: 687-94.
243. Minardi D, Garafolo F, Yehia M etal. Pressure-flow studies in men with benign prostatic hypertrophy before and after treatment with transurethral needle ablation. Urol. Int. 2001; 66: 89-93.
244. Bruskewitz R, Issa MM, Roehrborn CG etal. A prospective randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J. Urol. 1998; 159: 1588-93.
245. Leocádio Dean E, Frenkl Tara L, Stein Barry S. Office based transurethral needle ablation of the prostate with analgesia and local anesthesia. J. Urol. 2007; 178: 2052-4.
246. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur. Urol. 2003; 44: 89-93.
247. Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18months. J. Endourol. 2003; 17: 103-7.
248. Hill B, Belville W, Bruskewitz R etal. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J. Urol. 2004; 171: 2336-40.
249. Chapple CR, Issa MM, Woo H. Transurethral needle ablation (TUNA). A critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia. Eur. Urol. 1999; 35: 119-28.
250. Schatzl G, Madersbacher S, Lang T, Marberger M. The early postoperative morbidity of transurethral resection of the prostate and of four minimally invasive treatment alternatives. J. Urol. 1997; 158: 105-10.
251. Dahlstrand C, Waldén M, Deirsson G, Pettersson S. Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Br. J. Urol. 1995; 76: 614-18.
252. Ancona FC, Francisca EA, Witjes WP, Welling L, Debruyne FM, de la Rosette JJ. High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia (BPH): results of a prospective randomized study with 1year follow up. J. Urol. 1997; 158: 120-5.
253. Pace G, Selvaggio O, Palumbo F, Selvaggi FP. Initial experience with a new transurethral microwave thermotherapy treatment protocol "30-min TUMT". Eur. Urol. 2001; 39: 405-11.
254. de la Rosette JJ, Laguna MP, Pace G etal. Efficacy and safety of the new high-energy 30-min transurethral microwave thermotherapy: results of 1-year follow-up in a multicenter study. Tech. Urol. 2000; 6: 271-45.
255. Wagrell L, Schelin S, Nordling J etal. Feedback microwave thermotherapy versus TURP for clinical BPH: a randomized controlled multicenter study. Urology 2002; 60: 292-9.
256. Gravas S, Laguna P, Ehrnebo M, Wagrell L, Mattiasson A, de la Rosette JJMCH. Seeking evidence that cell kill guided thermotherapy gives results not inferior to those of transurethral prostate resection: results of a pooled analysis of 3 studies of feedback transurethral microwave thermotherapy. J. Urol. 2005; 174: 1002-6.
257. Mattiasson A, Wagrell L, Schelin S etal. Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 2007; 69: 91-6.
258. Alivizatos G, Ferakis N, Mitropoulos D, Skolarikos A, Livadas K, Kastriotis I. Feedback microwave thermotherapy with the ProstaLund Compact Device for obstructive benign prostatic hyperplasia: 12-month response rates and complications. J. Endourol. 2005; 19: 72-8.
259. Blute ML, Tomera KM, Hellerstein DK etal. Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: results of the United States Prostatron Cooperative Study. J. Urol. 1993; 150: 1591-6.
260. Vesely S, Knutson T, Dicuio M, Damber JE, Dahlstrand C. Transurethral microwave thermotherapy: clinical results after 11years of use. J. Endourol. 2005; 19: 730-3.
261. Wagrell L, Schelin S, Nordling J etal. Three-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 2004; 64: 698-702.
262. Rodrigues NN, Claro JA, Cortado PL. Ejaculatory dysfunction after transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia. J. Endourol. 1994; 8: 217-19.
263. Francisca EA, d'Ancona FC, Hendriks JC, Kiemeney LA, Debruyne FM, de la Rosette JJ. Quality of life assessment in patients treated with lower energy thermotherapy (Prostasoft 2.0): results of a randomized transurethral microwave thermotherapy versus sham study. J. Urol. 1997; 158: 1839-44.
264. de la Rosette JJ, de Wildt MJ, Hofner K, Carter SS, Debruyne FM, Tubaro A. High energy thermotherapy in the treatment of benign prostatic hyperplasia: results of the European Benign Prostatic Hyperplasia Study Group. J. Urol. 1996; 156: 97-101.
265. De Wildt MJ, Debruyne FM, de la Rosette JJ. High-energy transurethral microwave thermotherapy: a thermoablative treatment for benign prostatic obstruction. Urology 1996; 48: 416-23.
266. Gravas S, Laguna P, Kiemeney LALM, de la Rosette JJMCH. Durability of 30-min high-energy transurethral microwave therapy for treatment of benign prostatic hyperplasia: a study of 213 patients with and without urinary retention. Urology 2007; 69: 854-8.
267. Miller PD, Kastner C, Ramsey EW, Parsons K. Cooled thermotherapy for the treatment of benign prostatic hyperplasia: durability of results obtained with the Targis System. Urology 2003; 61: 1160-4.
268. Tan AH, Nott L, Hardie WR, Chin JL, Denstedt JD, Razvi H. Long-term results of microwave thermotherapy for symptomatic benign prostatic hyperplasia. J. Endourol. 2005; 19: 1191-5.
269. Masood S, Djaladat H, Kouriefs C, Keen M, Palmer JH. The 12-year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. BJU Int. 2004; 94: 1271-4.
270. Shore ND, Dineen MK, Saslawsky MJ, Lumerman JH, Corica AP. A temporary intraurethral prostatic stent relieves prostatic obstruction following transurethral microwave thermotherapy. J. Urol. 2007; 177: 1040-6.
271. Dineen MK, Shore ND, Lumerman JH, Saslawsky MJ, Corica AP. Use of a temporary prostatic stent after transurethral microwave thermotherapy reduced voiding symptoms and bother without exacerbating irritative symptoms. Urology 2008; 71: 873-7.
272. Perry MJ, Roodhouse AJ, Gidlow AB etal. Thermo-expandable intraprostatic stents in bladder outlet obstruction: an 8-year study. BJU Int. 2002; 90: 216-23.
273. Gesenberh A, Sintermann R. Management of benign prostatic hyperplasia in high risk patients: long-term experience with the Memotherm stent. J. Urol. 1998; 160: 72-6.
274. Thomas PJ, Britton JP, Harrison NW. The Prostakath stent: four years' experience. Br. J. Urol. 1993; 71: 430-2.
275. Shah DK, Kapoor R, Badlani GH. Experience with urethral stent explantation. J. Urol. 2003; 169: 1398-400.
276. Grise P, Plante M, Palmer J etal. Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur. Urol. 2004; 46: 496-502.
277. Goya N, Ishikawa N, Ito F, Kobayashi C, Tomizawa Y, Toma H. Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results. J. Urol. 2004; 172: 1017-20.
278. Sakr M, Eid A, Shoukry M, Fayed A. Transurethral ethanol injection therapy of benign prostatic hyperplasia: four-year follow-up. Int. J. Urol. 2009; 16: 196-201.
279. Plante MK, Marks LS, Anderson R etal. Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J. Urol. 2007; 177: 1030-5.
280. Mutaguchi K, Matsubara A, Kajiwara M etal. Transurethral ethanol injection for prostatic obstruction: an excellent treatment strategy for persistent urinary retention. Urology 2006; 68: 307-11.
281. Ilie CP, Chancellor MB, Chuang YC, Dan M. Intraprostatic botulinum toxin injection in patients with benign prostatic enlargement. J. Med. Life 2009; 2: 338-42.
282. Silva J, Silva C, Saraiva L etal. Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur. Urol. 2008; 53: 153-9.
283. Silva J, Pinto R, Carvalho T etal. Intraprostatic botulinum toxin type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol. 2009; 9: 9.
284. Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 2009; 73: 90-4.
285. Kuo HC, Liu HT. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand. J. Urol. Nephrol. 2009; 43: 206-11.
286. Jaidane M, Arfa NB, Hmida W etal. Effect of transurethral resection of the prostate on erectile function: a prospective comparative study. Int. J. Impot. Res. 2010; 22: 146-51.
287. Meng F, Gao B, Fu Q etal. Change of sexual function in patients before and after Ho:YAG laser enucleation of the prostate. J. Androl. 2007; 28: 259-61.
288. Ohigashi T, Murai M. Transurethral microwave thermotherapy. Jpn. J. Endourol. ESWL 2003; 16: 41-6. (In Japanese.)
289. Gravas S, Laguna MP, de la Rosette JJMCH. Efficacy and safety of intraprostatic temperature-controlled microwave thermotherapy in patients with benign prostatic hyperplasia: results of a prospective, open-label, single-center study with 1-year follow-up. J. Endourol. 2003; 17: 425-30.
290. Soleimani M, Hosseini SY, Aliasgari M, Dadkhah F, Lashay A, Amini E. Erectile dysfunction after prostatectomy: an evaluation of the risk factors. Scand. J. Urol. Nephrol. 2009; 43: 277-81.
291. Kumar R, Nehra A, Jacobson DJ etal. Alpha-blocker use is associated with decreased risk of sexual dysfunction. Urology 2009; 74: 82-8.
292. Rosen R, Seftel A, Roehrborn CG. Effects of alfuzosin 10mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. Int. J. Impot. Res. 2007; 19: 480-5.
293. Mondaini N, Gontero P, Giubilei G etal. Finasteride 5mg and sexual side effects: how many of these are related to a nocebo phenomenon? J. Sex. Med. 2007; 4: 1708-12.
294. Andriole GL, Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur. Urol. 2003; 44: 82-8.
295. Yoshida K, Negishi S, Ishii Y etal. Clinical study of antiandrogen therapy of the patients with benign prostatic hyperplasia: comparative studies of chlormadinone acetate (CMA) between 25mg tablets twice a day and 50mg long-acting tablet once a day. Shinryo to Shinyaku 1995; 32: 1269-79. (In Japanese.)
296. Vallancien G, Emberton M, Alcaraz A etal. Alfuzosin 10mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int. 2008; 101: 847-52.
297. Narayan P, Lepor H. Long-term, open-label, Phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 466-70.
298. Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY, CUSP Investigators. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. Clin. Ther. 1995; 17: 956-69.
299. Homma Y, Kawabe K, Tsukamoto T etal. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int. J. Urol. 1996; 3: 261-6.
300. Yamaguchi O, Nishizawa O, Takeda M etal. Clinical Guideline for Overactive Bladder. Rev. edn. Blackwell, Tokyo, 2007.
301. Homma Y, Kawabe K, Tsukamoto T etal. Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int. J. Urol. 1996; 3: 267-73.
302. Nishizawa O, Araki I, Ishizuka O etal. Clinical Guideline for Nocturia. Blackwell, Tokyo, 2009.
303. Abrams P, Chapple C, Khoury S etal. Evaluation and treatment of lower urinary tract symptoms in older men. J. Urol. 2009; 181: 1779-87.
304. Marks LS, Roehrborn CG, Wolford E, Wilson TH. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. J. Urol. 2007; 177: 1408-13.
305. Koch WF, Ezz el Din K, de Wildt MJAM, Debruyne FMJ, de la Rosette JJMCH. The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J. Urol. 1996; 155: 186-9.
306. th edn. Saunders, Philadelphia, 2007; 2896.
307. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J. Urol. 2003; 170: 498-502.
308. Schulman CC, Lock TMTW, Buzelin J-M etal. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J. Urol. 2001; 166: 1358-63.
309. Kawabe K, Homma Y, Kubota K, Sozu T, Tamsulosin Long-term Study Group. How frequent are invasive therapies required in patients with receiving tamsulosin for benign prostatic hyperplasia? A retrospective long-term study. Int. J. Urol. 2006; 13: 127-31.
310. Ichioka K, Ohara H, Terada N etal. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. Int. J. Urol. 2004; 11: 870-5.
311. de la Rosette JJMCH, Kortman BBM, Rossi C, Sonke GS, Floratos DL, Kiemeney LALM. Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms. J. Urol. 2002; 167: 1734-9.
312. Yamanishi T, Tatsumiya K, Furuya N etal. Long-term efficacy of tamsulosin in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in real-life practice. UroToday Int. J. 2009; 2: doi:10.3834/uij.1944-5784.2009.02.01.
313. 1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scand. J. Urol. Nephrol. 2007; 41: 422-9.
314. 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride. Scand. J. Urol. Nephrol. 2010; 44: 38-45.
315. Roehrborn CG, Siami P, Barkin J etal. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 2010; 57: 123-31.
316. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004; 94: 817-20.
317. Blake-James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systemic review and metaanalysis. BJU Int. 2007; 99: 85-96.
318. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α-blockers. Eur. Urol. 2009; 56: 534-43.
319. MacDiarmid SA, Peters KM, Chen A etal. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin. Proc. 2008; 83: 1002-10.
320. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin addon therapy to α-blocker treated men with residual urgency and frequency. J. Urol. 2009; 182: 2825-30.
321. Nishizawa O, Yamaguchi O, Takeda M, Yokoyama O, for the TAABO Study Group. Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. LUTS 2011; 3: 29-35.
322. Yamaguchi O, Kakizaki H, Homma Y etal. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms -ASSIST, randomized controlled study. Urology 2011; 78: 126-33.
323. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Viersen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur. Urol. 2003; 44: 461-6.
324. Chung B-H, Roehrborn CG, Siami P etal. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis. 2009; 12: 152-9.
325. Emberton M etal. The effects of prostatectomy on symptom severity and quality of life. Br. J. Urol. 1996; 77: 233-47.
326. Hakenberg OW etal. The follow-up of patients with unfavourable early results of transurethral prostatectomy. BJU Int. 1999; 84: 799-804.
327. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int. 2004; 93: 745-50.
328. Van Venrooij GE, von Melick HHE, Boon TA. Comparison of outcomes of transurethral prostate resection in urodynamically unobstructed or equivocal men. Urology 2003; 62: 672-6.
329. Robertson AS, Griffiths C, Neal DE. Conventional urodynamics and ambulatory monitoring in the definition and management of bladder outflow obstruction. J. Urol. 1996; 155: 506-11.
330. Javle P, Jenkins SA, Machin DG etal. Grading of benign prostatic obstruction can predict the outcome of transurethral prostatectomy. J. Urol. 1998; 160: 1713-17.
331. Machino R, Kakizaki H, Ameda K etal. Detrusor instability with equivocal obstruction: a predictor of unfavorable symptomatic outcomes after transurethral prostatectomy. Neurourol. Urodyn. 2002; 21: 444-9.
332. Seki N, Takei M, Yamaguchi A, Naito S. Analysis of prognostic factors regarding the outcome after a transurethral resection for symptomatic benign prostatic enlargement. Neurourol. Urodyn. 2006; 25: 428-32.
333. Abrams P. In support of pressure flow studies for evaluating men with lower urinary tract symptoms. Urology 1994; 44: 143-5.
334. McConnell JD. Why pressure-flow studies should be optional and not mandatory studies for evaluating men with benign prostatic hyperplasia. Urology 1994; 44: 156-8.
335. Homma Y. Pressure flow studies in benign prostatic hyperplasia: to do or not to do for the patient? BJU Int. 2001; 87: 19-23.
336. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of transurethral resection of prostate for bladder outlet obstruction. J. Urol. 2005; 174: 1887-91.
337. van Venrooij GE, Boon TA, de Gier RP. International prostate symptom score and quality of life assessment versus urodynamic parameters in men with benign prostatic hyperplasia symptoms. J. Urol. 1995; 153: 1516-19.
338. Homma Y, Yamaguchi T, Kondo Y, Horie S, Takahashi S, Kitamura T. Significance of nocturia in the international prostate symptom score for benign prostatic hyperplasia. J. Urol. 2002; 167: 172-6.
339. Rohrmann S, Giovannucci E, Willett WC, Platz EA. Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am. J. Clin. Nutr. 2007; 85: 523-9.
340. Galeone C, Pelucchi C, Talamini R etal. Onion and garlic intake and the odds of benign prostatic hyperplasia. Urology 2007; 70: 672 -6.
341. Bravi F, Bosetti C, Dal Maso L etal. Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia. Urology 2006; 67: 1205-11.
342. Bravi F, Bosetti C, Dal Maso L etal. Food groups and risk of benign prostatic hyperplasia. Urology 2006; 67: 73-9.
343. Ambrosini GL, de Klerk NH, Mackerras D, Leavy J, Fritschi L. Dietary patterns and surgically treated benign prostatic hyperplasia: a case control study in Western Australia. BJU Int. 2008; 101: 853-60.
344. Tavani A, Longoni E, Bosetti C etal. Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia: a case-control study from Italy. Eur. Urol. 2006; 50: 549-54.
345. Fritschi L, Tabrizi J, Leavy J, Ambrosini G, Timperio A. Risk factors for surgically treated benign prostatic hyperplasia in Western Australia. Public Health 2007; 121: 781-9.
346. Crispo A, Talamini R, Gallus S etal. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. Urology 2004; 64: 717-22.
347. Platz EA, Rimm EB, Kawachi I etal. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. Am. J. Epidemiol. 1999; 149: 106-15.
348. Atsui M. Epidemiological study on diet, smoking and alcohol drinking in the relationship to prostatic weight. Jpn. J. Urol. 1997; 88: 950-6.
349. Lo KL, Chan MCK, Wong A, Hou SM, Ng CF. Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia. Int. Urol. Nephrol. 2010; 42: 7-12.
350. Daly P, Connolly S, Rogers E, Sweeney P. Management outcome of acute urinary retention. Model of prediction. Urol. Int. 2009; 83: 39-43.
351. Williams G, White R. Experience with the Memotherm permanently implanted prostatic stent. Br. J. Urol. 1995; 76: 337-40.
352. Gesenberg A, Sintermann R. Management of benign prostatic hyperplasia in high risk patients: Long-term experience with the Memotherm stent. J. Urol. 1998; 160: 72-6.
353. Braf Z, Chen J, Sofer M etal. Intraprostatic metal stents (Prostakath and Urospiral): more than 6years' clinical experience with 110 patients. J. Endourol. 1996; 10: 555-8.
354. Hussain M, Greenwell TJ, Shah J etal. Long-term results of a self-expanding wallstent in the treatment of urethral stricture. BJU Int. 2004; 94: 1037-9.
355. Vanderbrink BA, Rastinehad AR, Badlani GH. Prostatic stents for the treatment of benign prostatic hyperplasia. Curr. Opin. Urol. 2007; 17: 1-6.
356. Masumori N, Tsukamoto T, Iwasawa A etal. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urol. Int. 2009; 83: 49-54.